600513 联环药业
已收盘 05-15 15:00:00
资讯
新帖
简况
联环药业最新公告：控股子公司获维生素B12注射液药品补充申请批准通知书
证券之星 · 05-11
联环药业最新公告：控股子公司获维生素B12注射液药品补充申请批准通知书
每周股票复盘：联环药业（600513）LH-1801片Ⅲ期临床主要终点符合预期
证券之星 · 05-10
每周股票复盘：联环药业（600513）LH-1801片Ⅲ期临床主要终点符合预期
联环药业（600513）披露1类新药LH-1801片Ⅲ期单药临床试验揭盲结果，5月8日股价下跌3.14%
证券之星 · 05-08
联环药业（600513）披露1类新药LH-1801片Ⅲ期单药临床试验揭盲结果，5月8日股价下跌3.14%
每周股票复盘：联环药业（600513）Q1营收增29.14%
证券之星 · 05-02
每周股票复盘：联环药业（600513）Q1营收增29.14%
联环药业(600513)3月31日股东户数4.94万户，较上期增加4.14%
证券之星 · 04-28
联环药业(600513)3月31日股东户数4.94万户，较上期增加4.14%
图解联环药业一季报：第一季度单季净利润同比下降72.14%
证券之星 · 04-28
图解联环药业一季报：第一季度单季净利润同比下降72.14%
股市必读：联环药业年报 - 第四季度单季净利润同比下降640.94%
证券之星 · 04-22
股市必读：联环药业年报 - 第四季度单季净利润同比下降640.94%
诺和诺德与OpenAI达成战略合作；再生元牵手Telix
21世纪经济报道 · 04-15
诺和诺德与OpenAI达成战略合作；再生元牵手Telix
联环药业(600513.SH)：盐酸甲氧氯普胺注射液获得药品注册证书
智通财经 · 04-14
联环药业(600513.SH)：盐酸甲氧氯普胺注射液获得药品注册证书
每周股票复盘：联环药业（600513）近5日3次登上龙虎榜
证券之星 · 04-12
每周股票复盘：联环药业（600513）近5日3次登上龙虎榜
4月7日联环药业（600513）龙虎榜数据
证券之星 · 04-07
4月7日联环药业（600513）龙虎榜数据
每周股票复盘：联环药业（600513）因换手率及涨幅两度登龙虎榜
证券之星 · 04-05
每周股票复盘：联环药业（600513）因换手率及涨幅两度登龙虎榜
联环药业（600513）披露控股子公司获得布美他尼注射液《药品补充申请批准通知书》，4月3日股价下跌9.98%
中金财经 · 04-03
联环药业（600513）披露控股子公司获得布美他尼注射液《药品补充申请批准通知书》，4月3日股价下跌9.98%
4月1日联环药业（600513）龙虎榜数据：北向资金净卖出4701.27万元
证券之星 · 04-01
4月1日联环药业（600513）龙虎榜数据：北向资金净卖出4701.27万元
2连板联环药业：LH-1801项目短期内不能取得上市批准
证券之星 · 03-30
2连板联环药业：LH-1801项目短期内不能取得上市批准
异动快报：联环药业（600513）3月30日9点58分触及涨停板
证券之星 · 03-30
异动快报：联环药业（600513）3月30日9点58分触及涨停板
每周股票复盘：联环药业（600513）控股子公司获尼可地尔片批件
证券之星 · 03-29
每周股票复盘：联环药业（600513）控股子公司获尼可地尔片批件
异动快报：联环药业（600513）3月27日9点55分触及涨停板
证券之星 · 03-27
异动快报：联环药业（600513）3月27日9点55分触及涨停板
联环药业最新公告：控股子公司尼可地尔片通过一致性评价
证券之星 · 03-26
联环药业最新公告：控股子公司尼可地尔片通过一致性评价
每周股票复盘：联环药业（600513）获间苯三酚注射液注册证
证券之星 · 03-22
每周股票复盘：联环药业（600513）获间苯三酚注射液注册证
加载更多
公司概况
公司名称：
江苏联环药业股份有限公司
所属行业：
医药制造业
上市日期：
2003-03-19
主营业务：
江苏联环药业股份有限公司的主营业务是药品生产、销售，化工原料、药品批发、药品等研发，技术成果转让、咨询。公司的主要产品是泌尿系统药、抗组胺药、心血管药、甾体激素、抗生素。公司是国家高新技术企业、国家知识产权示范企业、江苏省工业互联网发展示范企业（标杆工厂类）。
发行价格：
7.88
{"stockData":{"symbol":"600513","market":"SH","secType":"STK","nameCN":"联环药业","latestPrice":20.05,"timestamp":1778828400000,"preClose":20.94,"halted":0,"volume":19741709,"delay":0,"changeRate":-0.0425,"floatShares":285000000,"shares":285000000,"eps":-0.4028,"marketStatus":"已收盘","change":-0.89,"latestTime":"05-15 15:00:00","open":20.6,"high":20.77,"low":19.92,"amount":398000000,"amplitude":0.0406,"askPrice":20.05,"askSize":516,"bidPrice":20.04,"bidSize":26,"shortable":0,"etf":0,"ttmEps":-0.4028,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1779067800000},"marketStatusCode":5,"adr":0,"adjPreClose":20.94,"symbolType":"stock","openAndCloseTimeList":[[1778808600000,1778815800000],[1778821200000,1778828400000]],"highLimit":23.03,"lowLimit":18.85,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":285456270,"isCdr":false,"pbRate":4.48,"roa":"--","roe":"0.5%","epsLYR":-0.34,"committee":-0.572186,"marketValue":5723000000,"turnoverRate":0.0692,"status":1,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-05-18。","floatMarketCap":5723000000},"requestUrl":"/m/hq/s/600513","defaultTab":"news","newsList":[{"id":"2634404980","title":"联环药业最新公告：控股子公司获维生素B12注射液药品补充申请批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2634404980","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634404980?lang=zh_cn&edition=full","pubTime":"2026-05-11 17:22","pubTimestamp":1778491354,"startTime":"0","endTime":"0","summary":"联环药业(600513.SH)公告称，公司控股子公司常乐制药近日收到国家药监局核准签发的关于维生素B12注射液(1ml:0.5mg/1ml:1mg)《药品补充申请批准通知书》，批准变更药品处方及生产工艺等事项，并增加1ml:1mg规格，通过仿制药质量和疗效一致性评价。该药品主要用于巨幼细胞性贫血及神经炎的辅助治疗。2025年度全终端医院销售额为8004.93万元，研发投入约294万元。本次获批预计不会对近期经营业绩产生重大影响。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051100023812.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600513","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634571411","title":"每周股票复盘：联环药业（600513）LH-1801片Ⅲ期临床主要终点符合预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2634571411","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634571411?lang=zh_cn&edition=full","pubTime":"2026-05-10 01:24","pubTimestamp":1778347452,"startTime":"0","endTime":"0","summary":"截至2026年5月8日收盘，联环药业报收于21.57元，较上周的22.78元下跌5.31%。本周，联环药业5月6日盘中最高价报24.2元。公司公告汇总：LH-1801片20mg与40mg组HbA1c降幅显著优于安慰剂组，P值均<0.0001。公司公告汇总：联合用药试验显示LH-1801片疗效不劣于达格列净。公司公告汇总联环药业关于公司1类新药LH-1801片Ⅲ期单药临床试验揭盲结果的公告江苏联环药业股份有限公司1类新药LH-1801片Ⅲ期单药临床试验已完成揭盲，主要终点符合预期。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051000000233.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600513","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633439553","title":"联环药业（600513）披露1类新药LH-1801片Ⅲ期单药临床试验揭盲结果，5月8日股价下跌3.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2633439553","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633439553?lang=zh_cn&edition=full","pubTime":"2026-05-08 17:16","pubTimestamp":1778231788,"startTime":"0","endTime":"0","summary":"截至2026年5月8日收盘，联环药业报收于21.57元，较前一交易日下跌3.14%，最新总市值为61.57亿元。该股当日开盘23.5元，最高23.6元，最低21.55元，成交额达9.47亿元，换手率为14.84%。公司于近日披露《关于公司1类新药LH-1801片Ⅲ期单药临床试验揭盲结果的公告》。联合用药试验亦显示疗效不劣于达格列净。LH-1801片上市时间、市场竞争及商业化进程存在不确定性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050800030535.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","600513"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632641317","title":"每周股票复盘：联环药业（600513）Q1营收增29.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2632641317","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632641317?lang=zh_cn&edition=full","pubTime":"2026-05-02 02:09","pubTimestamp":1777658951,"startTime":"0","endTime":"0","summary":"截至2026年4月30日收盘，联环药业报收于22.78元，较上周的20.21元上涨12.72%。本周，联环药业4月30日盘中最高价报23.3元。联环药业当前最新总市值65.03亿元，在化学制药板块市值排名86/150，在两市A股市值排名2842/5200。股本股东变化股东户数变动截至2026年3月31日，联环药业股东户数为4.94万户，较2025年12月31日增加1963.0户，增幅4.14%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050200000368.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600513"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630374868","title":"联环药业(600513)3月31日股东户数4.94万户，较上期增加4.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630374868","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630374868?lang=zh_cn&edition=full","pubTime":"2026-04-28 17:32","pubTimestamp":1777368768,"startTime":"0","endTime":"0","summary":"证券之星消息，近日联环药业披露，截至2026年3月31日公司股东户数为4.94万户，较12月31日增加1963.0户，增幅为4.14%。在化学制药行业个股中，联环药业股东户数高于行业平均水平，截至3月31日，化学制药行业平均股东户数为3.57万户。从股价来看，2025年12月31日至2026年3月31日，联环药业区间涨幅为52.7%，在此期间股东户数增加1963.0户，增幅为4.14%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042800051345.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600513","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630129003","title":"图解联环药业一季报：第一季度单季净利润同比下降72.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630129003","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630129003?lang=zh_cn&edition=full","pubTime":"2026-04-28 03:58","pubTimestamp":1777319900,"startTime":"0","endTime":"0","summary":"证券之星消息，联环药业2026年一季报显示，一季度公司主营收入8.11亿元，同比上升29.14%；归母净利润642.48万元，同比下降72.14%；扣非净利润561.16万元，同比下降74.67%；负债率59.39%，投资收益-22.58万元，财务费用871.28万元，毛利率26.52%。财报数据概要请见下图:以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042800011128.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600513"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629059143","title":"股市必读：联环药业年报 - 第四季度单季净利润同比下降640.94%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629059143","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629059143?lang=zh_cn&edition=full","pubTime":"2026-04-22 01:11","pubTimestamp":1776791462,"startTime":"0","endTime":"0","summary":"来自：联环药业2025年归母净利润亏损9833.24万元，同比下降216.84%。2025年第四季度单季度主营收入6.29亿元，同比增长22.01%；单季度归母净利润亏损6327.03万元，同比下降640.94%；单季度扣非净利润亏损5505.18万元，同比下降35.7%。联环药业关于公司2025年度日常关联交易执行情况及2026年度日常关联交易预计的公告2025年度公司与非同一控制下关联方实际发生关联交易金额为1,580.62万元，与同一控制下关联方实际发生金额为5,255.09万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042200002859.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600513"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627045478","title":"诺和诺德与OpenAI达成战略合作；再生元牵手Telix","url":"https://stock-news.laohu8.com/highlight/detail?id=2627045478","media":"21世纪经济报道","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627045478?lang=zh_cn&edition=full","pubTime":"2026-04-15 08:01","pubTimestamp":1776211308,"startTime":"0","endTime":"0","summary":"政策动向国家医疗保障局持续开展定点医药机构违法违规使用医保基金自查自纠工作国家医疗保障局近日在全国范围内组织开展2026年定点医药机构违法违规使用医保基金自查自纠工作。自查自纠聚焦重点领域“逐渐细化、持续深化”。在既往心血管内科、骨科、血液净化、康复、医学影像、临床检验、肿瘤、麻醉、重症医学等9个重点领域的基础上，本年度进一步将口腔、内分泌、精神医学3个领域纳入自查自纠范围。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604153705224747.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604153705224747.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["NVO","02196","688177","IE00BZ1G4Q59.USD","BK4588","600513","REGN","LU1093756168.USD","NVOH","BK4007","002437","BK4585","LU0154236417.USD","603087","301087","600196","NVOX","300558","BK4599","LU1093756325.SGD","BK4532","IE00BKVL7J92.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627194334","title":"联环药业(600513.SH)：盐酸甲氧氯普胺注射液获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2627194334","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627194334?lang=zh_cn&edition=full","pubTime":"2026-04-14 16:59","pubTimestamp":1776157175,"startTime":"0","endTime":"0","summary":"智通财经APP讯，联环药业 发布公告，公司控股子公司新乡市常乐制药有限责任公司于近日收到国家药品监督管理局核准签发的关于盐酸甲氧氯普胺注射液的《药品注册证书》。2025年前三季度全国医院盐酸甲氧氯普胺注射液销售额达6,624.45万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1428299.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"联环药业(600513.SH)：盐酸甲氧氯普胺注射液获得药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["600513","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626124162","title":"每周股票复盘：联环药业（600513）近5日3次登上龙虎榜","url":"https://stock-news.laohu8.com/highlight/detail?id=2626124162","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626124162?lang=zh_cn&edition=full","pubTime":"2026-04-12 01:10","pubTimestamp":1775927419,"startTime":"0","endTime":"0","summary":"截至2026年4月10日收盘，联环药业报收于22.57元，较上周的27.68元下跌18.46%。本周，联环药业4月7日盘中最高价报27.79元。4月10日盘中最低价报22.55元。联环药业当前最新总市值64.43亿元，在化学制药板块市值排名86/150，在两市A股市值排名2824/5196。此次是近5个交易日内第3次上榜。沪深交易所2026年4月7日公布的交易公开信息显示，联环药业因有价格涨跌幅限制的日收盘价格跌幅偏离值达到7%的前五只证券登上龙虎榜。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041200000114.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600513","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625179936","title":"4月7日联环药业（600513）龙虎榜数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2625179936","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625179936?lang=zh_cn&edition=full","pubTime":"2026-04-07 17:14","pubTimestamp":1775553280,"startTime":"0","endTime":"0","summary":"证券之星消息，沪深交易所2026年4月7日公布的交易公开信息显示，联环药业因有价格涨跌幅限制的日收盘价格跌幅偏离值达到7%的前五只证券登上龙虎榜。此次是近5个交易日内第2次上榜。截至2026年4月7日收盘，联环药业报收于24.96元，下跌9.83%，换手率22.29%，成交量63.63万手，成交额16.59亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040700024145.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","600513"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625615903","title":"每周股票复盘：联环药业（600513）因换手率及涨幅两度登龙虎榜","url":"https://stock-news.laohu8.com/highlight/detail?id=2625615903","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625615903?lang=zh_cn&edition=full","pubTime":"2026-04-05 01:08","pubTimestamp":1775322490,"startTime":"0","endTime":"0","summary":"截至2026年4月3日收盘，联环药业报收于27.68元，较上周的25.61元上涨8.08%。本周，联环药业4月2日盘中最高价报32.27元，股价触及近一年最高点。本周关注点来自交易信息汇总：联环药业因日换手率达20%及三日涨幅偏离值累计达20%两度登上龙虎榜。交易信息汇总联环药业于2026年4月1日因有价格涨跌幅限制的日换手率达到20%进入龙虎榜，为近5个交易日内第2次上榜。截至公告日，常乐制药对该药品研发投入约541.60万元，2026年已获3个生产批件。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040500000076.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600513","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624476656","title":"联环药业（600513）披露控股子公司获得布美他尼注射液《药品补充申请批准通知书》，4月3日股价下跌9.98%","url":"https://stock-news.laohu8.com/highlight/detail?id=2624476656","media":"中金财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624476656?lang=zh_cn&edition=full","pubTime":"2026-04-03 17:12","pubTimestamp":1775207521,"startTime":"0","endTime":"0","summary":"近日，江苏联环药业股份有限公司控股子公司新乡市常乐制药有限责任公司收到国家药品监督管理局核准签发的布美他尼注射液《药品补充申请批准通知书》，批准增加1ml:0.5mg规格，并变更生产工艺参数、批量为420L、包材供应商。该药品适用于水肿性疾病、高血压、预防急性肾功能衰竭等。截至公告日，常乐制药对该药品研发投入约541.60万元，2026年已获3个生产批件。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260403/32124838.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0239","600513"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624599416","title":"4月1日联环药业（600513）龙虎榜数据：北向资金净卖出4701.27万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2624599416","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624599416?lang=zh_cn&edition=full","pubTime":"2026-04-01 17:20","pubTimestamp":1775035221,"startTime":"0","endTime":"0","summary":"证券之星消息，沪深交易所2026年4月1日公布的交易公开信息显示，联环药业因有价格涨跌幅限制的日换手率达到20%的前五只证券登上龙虎榜。此次是近5个交易日内第2次上榜。截至2026年4月1日收盘，联环药业报收于30.3元，上涨8.37%，换手率22.74%，成交量64.9万手，成交额19.07亿元。从龙虎榜公布的当日买卖数据来看，北向资金合计净卖出4701.27万元。深股通专用、沪股通专用为北向资金的交易席位。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040100031597.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","600513"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623319117","title":"2连板联环药业：LH-1801项目短期内不能取得上市批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2623319117","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623319117?lang=zh_cn&edition=full","pubTime":"2026-03-30 18:40","pubTimestamp":1774867250,"startTime":"0","endTime":"0","summary":"联环药业公告称，公司股票于3月27日、30日连续两个交易日收盘价格涨幅偏离值累计超过20%，触及异常波动。公司关注到市场上针对LH-1801项目的相关信息，LH-1801项目短期内不能取得上市批准，后续能否获得上市批准以及获批上市后的具体时间均存在重大不确定性。LH-1801是治疗糖尿病的SGLT-2抑制剂，目前市场已有8款左右治疗二型糖尿病的产品，即使LH-1801未来能够成功获批上市，也将面临较大竞争，敬请广大投资者注意二级市场交易风险，理性决策，审慎投资。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026033000028587.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600513","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623994362","title":"异动快报：联环药业（600513）3月30日9点58分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2623994362","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623994362?lang=zh_cn&edition=full","pubTime":"2026-03-30 10:00","pubTimestamp":1774836058,"startTime":"0","endTime":"0","summary":"证券之星3月30日盘中消息，9点58分联环药业触及涨停板。其所属行业化学制药目前上涨。领涨股为东诚药业。该股为创新药，流感，医药概念热股，当日创新药概念上涨1.07%，流感概念上涨0.55%，医药概念上涨0.53%。3月27日的资金流向数据方面，主力资金净流入1.22亿元，占总成交额18.28%，游资资金净流出5493.03万元，占总成交额8.21%，散户资金净流出6738.69万元，占总成交额10.07%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026033000005358.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600513","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623387406","title":"每周股票复盘：联环药业（600513）控股子公司获尼可地尔片批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2623387406","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623387406?lang=zh_cn&edition=full","pubTime":"2026-03-29 01:19","pubTimestamp":1774718349,"startTime":"0","endTime":"0","summary":"截至2026年3月27日收盘，联环药业报收于25.61元，较上周的22.44元上涨14.13%。本周，联环药业3月27日盘中最高价报25.61元。联环药业当前最新总市值73.11亿元，在化学制药板块市值排名79/150，在两市A股市值排名2523/5191。药品规格为5mg，包装规格包括12片/板×2板/袋×1袋/盒和30片/瓶，上市许可持有人和生产企业均为新乡市常乐制药有限责任公司。此次批准预计不会对公司近期经营业绩产生重大影响。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032900000111.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600513","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622168528","title":"异动快报：联环药业（600513）3月27日9点55分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2622168528","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622168528?lang=zh_cn&edition=full","pubTime":"2026-03-27 10:00","pubTimestamp":1774576847,"startTime":"0","endTime":"0","summary":"证券之星3月27日盘中消息，9点55分联环药业触及涨停板。其所属行业化学制药目前上涨。领涨股为美诺华。该股为创新药，医药，化妆品概念热股，当日创新药概念上涨1.66%，医药概念上涨1.38%，化妆品概念上涨1.08%。3月26日的资金流向数据方面，主力资金净流入2933.75万元，占总成交额9.13%，游资资金净流出439.67万元，占总成交额1.37%，散户资金净流出2494.08万元，占总成交额7.76%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032700015577.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600513","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622837742","title":"联环药业最新公告：控股子公司尼可地尔片通过一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2622837742","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622837742?lang=zh_cn&edition=full","pubTime":"2026-03-26 16:34","pubTimestamp":1774514071,"startTime":"0","endTime":"0","summary":"联环药业(600513.SH)公告称，公司控股子公司常乐制药近日收到国家药监局核准签发的尼可地尔片《药品补充申请批准通知书》，该药品已通过仿制药质量和疗效一致性评价。尼可地尔片用于治疗心绞痛，2024年度国内样本医院销售额约为6.35亿元。截至公告日，常乐制药针对该药品研发投入约720万元。本次获批预计不会对公司近期经营业绩产生重大影响。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032600029255.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600513","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621791889","title":"每周股票复盘：联环药业（600513）获间苯三酚注射液注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2621791889","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621791889?lang=zh_cn&edition=full","pubTime":"2026-03-22 03:23","pubTimestamp":1774120990,"startTime":"0","endTime":"0","summary":"截至2026年3月20日收盘，联环药业报收于22.44元，较上周的21.51元上涨4.32%。本周关注点公司公告汇总：联环药业获得间苯三酚注射液《药品注册证书》，视同通过仿制药一致性评价。公司公告汇总联环药业关于公司获得《药品注册证书》的公告江苏联环药业股份有限公司收到国家药品监督管理局核准签发的间苯三酚注射液《药品注册证书》，药品批准文号为国药准字H20263534，注册分类为化学药品4类，视同通过仿制药质量和疗效一致性评价。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032200001304.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","600513"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1778976053337,"stockEarnings":[{"period":"1week","weight":-0.0705},{"period":"1month","weight":-0.1558},{"period":"3month","weight":-0.001},{"period":"6month","weight":-0.1479},{"period":"1year","weight":1.2174},{"period":"ytd","weight":0.095}],"compareEarnings":[{"period":"1week","weight":-0.0107},{"period":"1month","weight":0.0269},{"period":"3month","weight":0.0131},{"period":"6month","weight":0.0363},{"period":"1year","weight":0.2232},{"period":"ytd","weight":0.042}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"江苏联环药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"49398人(较上一季度增加4.14%)","perCapita":"5778股","listingDate":"2003-03-19","address":"江苏省扬州市邗江区生物健康产业园健康一路9号","registeredCapital":"28545万元","survey":" 江苏联环药业股份有限公司的主营业务是药品生产、销售，化工原料、药品批发、药品等研发，技术成果转让、咨询。公司的主要产品是泌尿系统药、抗组胺药、心血管药、甾体激素、抗生素。公司是国家高新技术企业、国家知识产权示范企业、江苏省工业互联网发展示范企业（标杆工厂类）。","listedPrice":7.88},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"联环药业(600513)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供联环药业(600513)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"联环药业,600513,联环药业股票,联环药业股票老虎,联环药业股票老虎国际,联环药业行情,联环药业股票行情,联环药业股价,联环药业股市,联环药业股票价格,联环药业股票交易,联环药业股票购买,联环药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"联环药业(600513)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供联环药业(600513)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}